Exploring the Untargeted Cysteinome of Protein Kinases

webinar

Thu, 09 Dec 2021, 16:30 CET (Berlin)

Prof. Dr. Matthias Gehringer, University of Tübingen, Germany

Exploring the Untargeted Cysteinome of Protein Kinases

Protein kinases are now among the major drug targets with over 65 inhibitors approved since the groundbreaking approval of imatinib (Gleevec) in 2001. Covalent targeting approaches that have gained traction in recent years, have proven particularly useful in the protein kinase field. Typically, covalent inhibitors feature superior potency and efficacy as well as a prolonged duration of action. Of the >500 human protein kinases, the so-called “kinome”, almost 50% are characterized by the presence of an accessible, non-conserved cysteine residue in or around the ATP binding site. Addressing such cysteines by mild electrophiles, termed covalent “warheads”, enables the rational design of highly potent and selective protein kinase inhibitors as chemical probes or drugs. So far, however, only a small fraction of the protein kinases’ “cysteinome” has been addressed. In this talk, Matthias will present recent efforts toward the development of covalent inhibitors for protein kinases with a cysteine in the so-called “hinge region” using canonical and non-canonical warhead chemistry. Specifically, he will focus on inhibitors targeting TTK/MPS1, a kinase controlling the spindle assembly checkpoint, and S6K2/p70S6Kβ, a neglected member of the ribosomal protein S6 kinase family. Join us!

Current news

category
Software
Novel Scaffolds in the CHEMriya Update — Find Favorites with infiniSee 3.3
January 20, 2022 10:00
Novel scaffolds are one of the driving forces behind modern drug discovery. For a drug to be financially lucrative pharmaceutical companies require exclusivity over the production and distribution rights in the form of a patent. Yet, patents and the connected intellectual property (IP) are only granted to chemically novel drug...
Read on
category
Challenge
Winner of Winter 2020 Scientific Challenge: Vigneshwaran Namasivayam with Novel CD39 Inhibitors
December 16, 2021 11:40
We are happy and proud to announce the winner of the Winter 2020 Scientific Challenge: Vigneshwaran Namasivayam from the University of Bonn! In his project Vigneshwaran aimed to discover novel ectonucleoside triphosphate diphosphohydrolase-1 (also known as NTPDase1) inhibitors for the treatment of of cancer and infections. A very difficult task...
Read on
Drug Discovery Software SeeSAR Hephaestus
category
Software
Covalent Docking Software Update: SeeSAR 11.2 and CovXplorer Workflow
November 24, 2021 17:45
The covalent docking software update of SeeSAR 11.2 Hephaestus features a broad set of improvements and is accompanied by a new BioSolveIT workflow: CovXplorer provides users with a framework to conveniently explore covalent binding sites and ligands that can easily be modified to match the needs of the project. The...
Read on